Loading chat...
WV SB906
Bill
AI Summary
- Crystalline polymorph psilocybin would become lawful to prescribe, distribute, and market in West Virginia if approved by the FDA and rescheduled by the DEA
- Amends the West Virginia Uniform Controlled Substances Act (§60A-2-201 and §60A-2-204) to create an exception for FDA-approved psilocybin products
- Psilocybin currently remains classified as a Schedule I hallucinogenic substance under state law, with the new exception applying only to the specific crystalline polymorph formulation
- The Board of Pharmacy retains authority to administer controlled substance schedules and recommend changes to the Legislature based on federal actions
- Introduced February 10, 2026, by Senator Deeds and referred to the Senate Committee on Health and Human Resources
Legislative Description
Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
Health
Last Action
Completed legislative action
3/14/2026
Committee Referrals
Health & Human Resources3/5/2026
Health and Human Resources2/10/2026
Full Bill Text
No bill text available